APA
Click to copy
Aguilera, X., Hormazábal, J., Vial, C., Cortes, L. J., González, C., Rubilar, P., … Vial, P. M. (2022). SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes. MedRxiv.
Chicago/Turabian
Click to copy
Aguilera, X., Juan Hormazábal, C. Vial, L. J. Cortes, Claudia González, Paola Rubilar, M. Apablaza, et al. “SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes.” medRxiv (2022).
MLA
Click to copy
Aguilera, X., et al. “SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes.” MedRxiv, 2022.
BibTeX Click to copy
@article{x2022a,
title = {SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes},
year = {2022},
journal = {medRxiv},
author = {Aguilera, X. and Hormazábal, Juan and Vial, C. and Cortes, L. J. and González, Claudia and Rubilar, Paola and Apablaza, M. and Ramírez-Santana, M. and Icaza, Gloria and Núñez-Franz, Loreto and Castillo-Laborde, Carla and Ramírez-Riffo, Carolina and Pérez, C. and Quezada-Gate, Rubén and Said, M. and Vial, Pablo M.}
}
Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines technologies and heterologous boosters. In 120 randomly selected seropositive individuals from a population-based study, we conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response.